This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
by Kinjel Shah
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
by Zacks Equity Research
TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
by Kinjel Shah
AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
by Zacks Equity Research
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
by Kinjel Shah
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
PFE or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?
by Kinjel Shah
Those who own Pfizer's stock may stay invested to see how Pfizer's new growth drivers perform.
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
by Zacks Equity Research
AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
by Zacks Equity Research
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.
The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
by Zacks Equity Research
Apple, Novo Nordisk, RTX and FONAR are included in this Analyst Blog.
Top Research Reports for Apple, Novo Nordisk & RTX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Novo Nordisk A/S (NVO) and RTX Corporation (RTX), as well as a micro-cap stock FONAR Corporation (FONR).
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.
Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?
by Zacks Equity Research
HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
by Kinjel Shah
Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.